

Product Data Sheet

Cas No.:	1229-29-4	Cat. No.:	PC14686
Product Name:	Doxepin (hydrochloride).		
Product synonym:	盐酸多虑平;盐酸多塞平;N,N-二甲基-3-二苯并[b,e]-噁庚英-11(6H)亚基-丙胺盐酸盐;多虑平盐酸盐;多塞平盐酸盐;Doxepin Hydrochloride 多塞平盐酸盐;Doxepinhydrochloride (顺+反);多虑平;多虑平 盐酸盐(异构体混合物);盐酸多虑平(Doxepin Hydrochloride)杂质对照品;盐酸多虑平 (盐酸多塞平);盐酸多塞平 BP 93;盐酸多塞平 EP标准品;盐酸多塞平 USP标准品;盐酸多塞平 标准品;盐酸多塞平(异构体混合物);盐酸多塞平,对照品;11-(3-二甲基氨基亚丙基)-6,11-二氢二苯并[b,e]氧杂卓盐酸盐;N,N-二甲基-3-二苯并[B,E]-庚英-11(6H)亚基-丙胺盐酸盐;盐酸多噻平;11-(3-二甲基氨基亚丙基)-6,11-二氢二苯并[b,e]氧杂卓盐酸盐(异构体混合物)		
Chemical name:	Doxepin (hydrochloride).		
MF:	C19NOCLH22	FW:	315.8371
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	Cl[H].O1C2=C([H])C([H])=C([H])C([H])=C2/C(=C(\[H])/C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H])/C2=C([H])C([H])=C([H])C([H])=C2C1([H])[H]		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

组胺、5-羟色胺、肾上腺素能和毒蕈碱受体拮抗剂，Doxepin盐酸盐能抑制5-羟色胺和去甲肾上腺素的重吸收，有抗抑郁活性。

生物活性	<p>Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2. Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant.</p> <ul style="list-style-type: none"> Doxepin has therapeutic effects in atopic dermatitis, chronic urticaria, can improve cognitive processes, protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress. . 																								
体外研究(In Vitro)	<p>The protective effect of doxepin is associated with the enhancement of PSD-95 and synapsin 1 expression via PI3K/AKT/mTOR signaling pathway.</p> <p>.</p> <p>Medlife has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis</p> <table border="1" data-bbox="353 676 1513 900"> <tr> <td>Cell Line:</td><td>SH-SY5Y human neuroblastoma cell line</td></tr> <tr> <td>Concentration:</td><td>10 ng/ml</td></tr> <tr> <td>Incubation Time:</td><td>2 h</td></tr> <tr> <td>Result:</td><td>Improved the protein expression levels of PSD-95, synapsin 1 and p-AKT in SH-SY5Y cells, and decreased the p</td></tr> </table>	Cell Line:	SH-SY5Y human neuroblastoma cell line	Concentration:	10 ng/ml	Incubation Time:	2 h	Result:	Improved the protein expression levels of PSD-95, synapsin 1 and p-AKT in SH-SY5Y cells, and decreased the p																
Cell Line:	SH-SY5Y human neuroblastoma cell line																								
Concentration:	10 ng/ml																								
Incubation Time:	2 h																								
Result:	Improved the protein expression levels of PSD-95, synapsin 1 and p-AKT in SH-SY5Y cells, and decreased the p																								
体内研究(In Vivo)	<p>Doxepin (intraperitoneal injection of 1 mg/kg and 5 mg/kg doxepin once a day for 21 days) can protect against the Aβ1-42-induced memory impairment in rats.</p> <p>.</p> <p>Medlife has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="353 1125 1513 1349"> <tr> <td>Animal Model:</td><td>SD male rats.</td></tr> <tr> <td>Dosage:</td><td>1, 5mg/kg</td></tr> <tr> <td>Administration:</td><td>Doxepin (intraperitoneal injection of 1 mg/kg and 5 mg/kg doxepin once a day for 21 days)</td></tr> <tr> <td>Result:</td><td>Improved the protein expression levels of PSD-95 and synapsin 1 in hippocampus and temporal lobe, and decre</td></tr> </table>	Animal Model:	SD male rats.	Dosage:	1, 5mg/kg	Administration:	Doxepin (intraperitoneal injection of 1 mg/kg and 5 mg/kg doxepin once a day for 21 days)	Result:	Improved the protein expression levels of PSD-95 and synapsin 1 in hippocampus and temporal lobe, and decre																
Animal Model:	SD male rats.																								
Dosage:	1, 5mg/kg																								
Administration:	Doxepin (intraperitoneal injection of 1 mg/kg and 5 mg/kg doxepin once a day for 21 days)																								
Result:	Improved the protein expression levels of PSD-95 and synapsin 1 in hippocampus and temporal lobe, and decre																								
包装储存	<p>Sealed and stored at 4°C, away from moisture</p> <p>*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)</p>																								
	<p>体外研究:</p> <p>DMSO : ≥ 100 mg/mL (316.62 mM)</p> <p>H₂O : ≥ 50 mg/mL (158.31 mM)</p> <p>* "≥" means soluble, but saturation unknown.</p> <table border="1" data-bbox="353 1754 1513 2012"> <thead> <tr> <th rowspan="2">配制储备溶液</th> <th rowspan="2">溶剂体积 浓度</th> <th colspan="3">质量</th> </tr> <tr> <th>1 mM</th> <th>3.1662 mL</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td></td> <td>1 mM</td> <td>3.1662 mL</td> <td>15.8308 mL</td> <td>31.6616 mL</td> </tr> <tr> <td></td> <td>5 mM</td> <td>0.6332 mL</td> <td>3.1662 mL</td> <td>6.3323 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td>0.3166 mL</td> <td>1.5831 mL</td> <td>3.1662 mL</td> </tr> </tbody> </table> <p>* 产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复</p>	配制储备溶液	溶剂体积 浓度	质量			1 mM	3.1662 mL	5 mg	10 mg		1 mM	3.1662 mL	15.8308 mL	31.6616 mL		5 mM	0.6332 mL	3.1662 mL	6.3323 mL		10 mM	0.3166 mL	1.5831 mL	3.1662 mL
配制储备溶液	溶剂体积 浓度			质量																					
		1 mM	3.1662 mL	5 mg	10 mg																				
	1 mM	3.1662 mL	15.8308 mL	31.6616 mL																					
	5 mM	0.6332 mL	3.1662 mL	6.3323 mL																					
	10 mM	0.3166 mL	1.5831 mL	3.1662 mL																					

冻造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究：

建议根据您的[实验动物和给药方式](#)选择适当的溶解方案。以下溶解方案都建议先按照[体外研究](#)方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百

分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

溶解度数据

1. 建议依照次序添加每种溶剂： PBS

Solubility: 140 mg/mL (443.26 mM); Clear solution; Need ultrasonic

2. 建议依照次序添加每种溶剂： 10% DMSO 40% [PEG300](#) 5% [Tween-80](#) 45% saline

Solubility: ≥ 2.5 mg/mL (7.92 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.92 mM, 饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

3. 建议依照次序添加每种溶剂： 10% DMSO 90% ([20% SBE-β-CD in saline](#))

Solubility: ≥ 2.5 mg/mL (7.92 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.92 mM, 饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磷丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

4. 建议依照次序添加每种溶剂： 10% DMSO 90% [corn oil](#)

Solubility: ≥ 2.5 mg/mL (7.92 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.92 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。

*